A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2-391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy.

被引：3

作者：

Kasner, Margaret T.

Ritchie, Ellen K.

Cutler, David

Fetterly, Gerald J.

Kramer, Douglas

Hangauer, David

Thompson, James E.

机构：

[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Athenex, Cranford, NJ USA

[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[5] Kinex Pharmaceut Inc, Cranford, NJ USA

[6] Athenex, Buffalo, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.7043

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7043

引用

页数：5